Of timing and surrogates: a way forward for cancer chemoprevention

Clin Cancer Res. 2011 Jun 1;17(11):3509-11. doi: 10.1158/1078-0432.CCR-11-0643. Epub 2011 Apr 15.

Abstract

Cancer chemoprevention strategies are not widely implemented in clinical practice. Targeting biomarkers in patients with elevated risk of developing cancer by means of short-term administration of certain agents may be a strategy to minimize toxicities while maintaining efficacy in clinical trials that can be completed in years rather than decades.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Anticarcinogenic Agents / therapeutic use
  • Antineoplastic Agents / therapeutic use*
  • Biomarkers
  • Biomarkers, Tumor / antagonists & inhibitors
  • Celecoxib
  • Chemoprevention
  • Colorectal Neoplasms / drug therapy
  • Colorectal Neoplasms / prevention & control*
  • Cyclooxygenase 2 Inhibitors / therapeutic use
  • Humans
  • Pyrazoles / therapeutic use
  • Sulfonamides / therapeutic use
  • Sulindac / therapeutic use

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Anticarcinogenic Agents
  • Antineoplastic Agents
  • Biomarkers
  • Biomarkers, Tumor
  • Cyclooxygenase 2 Inhibitors
  • Pyrazoles
  • Sulfonamides
  • Sulindac
  • Celecoxib